Fluphenazine: Difference between revisions
m Adding "update inline" template for Cochrane reference |
→Effectiveness: Updated citation to latest published version |
||
Line 67: | Line 67: | ||
==Effectiveness== |
==Effectiveness== |
||
A 2013 [[Cochrane (organisation)|Cochrane]] review found that fluphenazine's was an imperfect treatment and other inexpensive drugs less associated with side effects may be an just as good in people with schizophrenia |
A 2013 [[Cochrane (organisation)|Cochrane]] review found that fluphenazine's was an imperfect treatment and other inexpensive drugs less associated with side effects may be an just as good in people with schizophrenia.<ref>{{Cite journal|last=Matar|first=Hosam E|last2=Almerie|first2=Muhammad Qutayba|last3=Sampson|first3=Stephanie J|date=2018-06-12|title=Fluphenazine (oral) versus placebo for schizophrenia|url=http://dx.doi.org/10.1002/14651858.cd006352.pub3|journal=Cochrane Database of Systematic Reviews|doi=10.1002/14651858.cd006352.pub3|issn=1465-1858}}</ref> |
||
==Other animals== |
==Other animals== |
Revision as of 08:15, 8 December 2018
Clinical data | |
---|---|
Trade names | Prolixin, Modecate, Moditen others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682172 |
Pregnancy category |
|
Routes of administration | by mouth, IM, depot injection (fluphenazine decanoate) |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 2.7% (by mouth) |
Metabolism | unclear[1] |
Elimination half-life | IM 15 hours (HCL), 7-10 days (decanoate)[1] |
Excretion | Urine, faeces |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.639 |
Chemical and physical data | |
Formula | C22H26F3N3OS |
Molar mass | 437.523 g/mol g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Fluphenazine, sold under the brand names Prolixin among others, is an antipsychotic medication.[1] It is used in the treatment of chronic psychoses such as schizophrenia,[1][2] and appears to be about equal in effectiveness to low-potency antipsychotics like chlorpromazine.[3] It is given by mouth, injection into a muscle, or just under the skin.[1] There is also a long acting injectable version that may last for up to four weeks.[1] Fluphenazine decanoate, the depot injection form of fluphenazine, should not be used by people with severe depression.[4]
Common side effects include movement problems, sleepiness, depression and increased weight.[1] Serious side effects may include neuroleptic malignant syndrome, low white blood cell levels, and the potentially permanent movement disorder tardive dyskinesia.[1] In older people with psychosis as a result of dementia it may increase the risk of dying.[1] It may also increase prolactin levels which may result in milk production, enlarged breasts in males, impotence, and the absence of menstrual periods.[1] It is unclear if it is safe for use in pregnancy.[1] Fluphenazine is a typical antipsychotic of the phenothiazine class.[1] Its mechanism of action is not entirely clear but believed to be related to its ability to block dopamine receptors.[1] In up to 40% of those on long term phenothiazines, liver function tests become mildly abnormal.[5]
Fluphenazine came into use in 1959.[6] The injectable form is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[7] It is available as a generic medication.[1] In the United States the tablets costs between 0.22 and 0.42 USD per day for a typical dose.[1] The wholesale cost in the developing world of the long acting form is between 0.20 and 6.20 USD per injection as of 2014.[8] It was discontinued in Australia around mid 2017.[9]
Effectiveness
A 2013 Cochrane review found that fluphenazine's was an imperfect treatment and other inexpensive drugs less associated with side effects may be an just as good in people with schizophrenia.[10]
Other animals
In horses, it is sometimes given by injection as an anxiety-relieving medication, though there are many negative common side effects and it is forbidden by many equestrian competition organizations.[11]
References
- ^ a b c d e f g h i j k l m n o "fluphenazine decanoate". The American Society of Health-System Pharmacists. Archived from the original on 2015-12-08. Retrieved Dec 1, 2015.
{{cite web}}
: Unknown parameter|deadurl=
ignored (|url-status=
suggested) (help) - ^ "Product Information: Modecate (Fluphenazine Decanoate Oily Injection )". TGA eBusiness Services. Bristol-Myers Squibb Australia Pty Ltd. 1 November 2012. Archived from the original (PDF) on 2 August 2017. Retrieved 9 December 2013.
{{cite web}}
: Unknown parameter|deadurl=
ignored (|url-status=
suggested) (help) - ^ Tardy M, Huhn M, Engel RR, Leucht S (August 2014). "Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia". The Cochrane Database of Systematic Reviews. 8 (8): CD009230. doi:10.1002/14651858.CD009230.pub2. PMID 25087165.
- ^ "Modecate Injection 25mg/ml - Patient Information Leaflet (PIL) - (eMC)". www.medicines.org.uk. Retrieved 2017-11-06.
- ^ "Fluphenazine". livertox.nih.gov. Retrieved 2017-11-06.
- ^ McPherson, Edwin M. (2007). Pharmaceutical Manufacturing Encyclopedia (3rd ed.). Burlington: Elsevier. p. 1680. ISBN 9780815518563.
{{cite book}}
: Unknown parameter|name-list-format=
ignored (|name-list-style=
suggested) (help) - ^ "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Archived from the original (PDF) on 13 December 2016. Retrieved 8 December 2016.
{{cite web}}
: Unknown parameter|deadurl=
ignored (|url-status=
suggested) (help) - ^ "Fluphenazine Decanoate". International Drug Price Indicator Guide. Archived from the original on 2 August 2017. Retrieved 2 December 2015.
{{cite web}}
: Unknown parameter|deadurl=
ignored (|url-status=
suggested) (help) - ^ Rossi S, ed. (July 2017). "Fluphenazine - Australian Medicines Handbook". Australian Medicines Handbook. Adelaide, Australia: Australian Medicines Handbook Pty Ltd. Retrieved 8 August 2017.
- ^ Matar, Hosam E; Almerie, Muhammad Qutayba; Sampson, Stephanie J (2018-06-12). "Fluphenazine (oral) versus placebo for schizophrenia". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd006352.pub3. ISSN 1465-1858.
- ^ Loving NS (31 March 2012). "Effects of Behavior-Modifying Drug Investigated (AAEP 2011)". The Horse Media Group. Archived from the original on 6 January 2017. Retrieved 13 December 2016.
{{cite web}}
: Unknown parameter|deadurl=
ignored (|url-status=
suggested) (help)